Obseva (OBSV) Issues Earnings Results

Obseva (NASDAQ:OBSV) issued its quarterly earnings data on Thursday. The company reported ($0.42) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.46) by $0.04, Morningstar.com reports.

Shares of NASDAQ:OBSV traded down $0.57 during midday trading on Friday, reaching $15.35. The company’s stock had a trading volume of 26,596 shares, compared to its average volume of 137,080. The company has a market capitalization of $584.80 million, a PE ratio of -6.82 and a beta of 1.75. Obseva has a 12-month low of $9.05 and a 12-month high of $20.35.

OBSV has been the topic of a number of recent research reports. HC Wainwright set a $30.00 target price on shares of Obseva and gave the stock a “buy” rating in a research report on Wednesday, July 25th. Zacks Investment Research downgraded shares of Obseva from a “buy” rating to a “hold” rating in a research report on Wednesday, October 10th. Leerink Swann initiated coverage on shares of Obseva in a research report on Wednesday, August 15th. They issued an “outperform” rating and a $25.00 target price on the stock. Credit Suisse Group initiated coverage on shares of Obseva in a research report on Thursday, July 19th. They issued an “outperform” rating and a $24.00 target price on the stock. Finally, Wedbush initiated coverage on shares of Obseva in a research report on Monday, August 6th. They issued an “outperform” rating and a $34.00 target price on the stock. Eight equities research analysts have rated the stock with a buy rating, The stock has an average rating of “Buy” and an average target price of $29.43.

Several large investors have recently added to or reduced their stakes in the company. DRW Securities LLC grew its position in shares of Obseva by 55.0% in the 2nd quarter. DRW Securities LLC now owns 33,812 shares of the company’s stock worth $512,000 after buying an additional 12,000 shares during the period. US Bancorp DE purchased a new stake in Obseva during the 2nd quarter valued at about $197,000. Tiverton Asset Management LLC purchased a new stake in Obseva during the 2nd quarter valued at about $224,000. Jane Street Group LLC purchased a new stake in Obseva during the 2nd quarter valued at about $349,000. Finally, First Manhattan Co. grew its position in Obseva by 1.6% during the 3rd quarter. First Manhattan Co. now owns 1,532,466 shares of the company’s stock valued at $27,630,000 after purchasing an additional 23,500 shares during the last quarter. 68.33% of the stock is currently owned by hedge funds and other institutional investors.

COPYRIGHT VIOLATION WARNING: “Obseva (OBSV) Issues Earnings Results” was first posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this report on another publication, it was illegally stolen and reposted in violation of international copyright legislation. The correct version of this report can be viewed at https://www.dispatchtribunal.com/2018/11/10/obseva-obsv-issues-earnings-results.html.

About Obseva

ObsEva SA, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for women suffering from reproductive health and pregnancy disorders. It is developing OBE2109, an oral gonadotropin-releasing hormone receptor antagonist for the treatment of pain associated with endometriosis and heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women; nolasiban, an oral oxytocin receptor antagonist to enhance clinical pregnancy and live birth rates in women undergoing in vitro fertilization; and OBE022, an oral and selective prostaglandin F2a, or PGF2a receptor antagonist, as a once daily treatment for preterm labor in weeks 24 to 34 of gestational age.

See Also: Growth Stocks, What They Are, What They Are Not

Earnings History for Obseva (NASDAQ:OBSV)

Receive News & Ratings for Obseva Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Obseva and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply